$42 Million

Frequency Therapeutics, Inc.


Sole Placement Agent, July 2020

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company advancing a novel approach in regenerative medicine that uses combinations of small molecules to create potentially disease-modifying therapeutics that restore the healthy functioning of tissues. The Company developed its progenitor cell activation platform, or PCA platform, to design proprietary small-molecule combinations that selectively activate progenitor cells located at targeted sites within the body. The Company’s lead proprietary product candidate, FX-322, is being developed to treat sensorineural hearing loss, or SNHL, the most prevalent type of hearing loss. The Company is also applying its PCA platform in a second program for the remyelination of nerve fibers in patients with multiple sclerosis.